NeuroSense Therapeutics Ltd. (NRSN)
| Market Cap | 21.58M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -11.28M |
| Shares Out | 17.33M |
| EPS (ttm) | -0.83 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 33,134 |
| Open | 1.240 |
| Previous Close | 1.260 |
| Day's Range | 1.170 - 1.285 |
| 52-Week Range | 0.400 - 2.330 |
| Beta | 1.56 |
| Analysts | Strong Buy |
| Price Target | 7.50 (+502.41%) |
| Earnings Date | Apr 5, 2024 |
About NRSN
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under pr... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for NRSN stock is "Strong Buy" and the 12-month stock price forecast is $7.5.
News
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease
CAMBRIDGE, Mass. , April 22, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
Presentation by Massachusetts General Chair of Neurology Merit Cudkowicz, MD, shows both positive clinical effects and consistent trend toward impact on Neurofilament biomarker levels CAMBRIDGE, Mass....
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024
Emerging Science (Late-Breaker Equivalent) Abstract To Be Presented At 5:30PM Local Time Highlights Phase 2 PARADIGM Outcomes CAMBRIDGE, Mass. , April 12, 2024 /PRNewswire/ -- NeuroSense Therapeutics ...
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
CAMBRIDGE, Mass. , April 10, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics
NeuroSense will leverage its extensive experience in biomarker utilization to advance early diagnosis and treatment in the neurodegeneration field Lonza to develop, optimize, and qualify a method util...
NeuroSense Announces Year End 2023 Financial Results and Provides Business Update
CAMBRIDGE, Mass. , April 5, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
PrimeC demonstrated a clinically meaningful effect on quality of life and on complication free-survival for patients with ALS Standard ALS Measure ALSFRS-R already demonstrated a statistically signifi...
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
CAMBRIDGE, Mass. , Feb. 7, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense's (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024
HERZLIYA, ISRAEL / ACCESSWIRE / January 30, 2024 / Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that kills the nerve cells controlling the voluntary movement of muscles. I...
NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts
End of Phase 2 meeting with the FDA and EMA expected in Q2 2024 and several biomarker study results anticipated as early as Q1 2024, as the Company advances partnership discussions CAMBRIDGE, Mass. , ...
NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement
This notification has no immediate effect on the listing or trading of NeuroSense's ordinary shares on the Nasdaq Capital Market CAMBRIDGE, Mass. , Dec. 27, 2023 /PRNewswire/ -- NeuroSense Therapeutic...
NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial
A statistically significant, 37.4% difference (P=0.03), slowing of disease progression in ALSFRS-R, in patients treated with PrimeC compared to placebo, in the pre-specified Per Protocol (PP) populat...
NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints
Top-Line Results from 6-month double-blind Phase 2b PARADIGM trial with NeuroSense's lead drug candidate for ALS, PrimeC, include: PrimeC achieved primary safety and tolerability endpoints with a safe...
NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023
Data to be announced in a premarket press release followed by a conference call at 8:30 am ET CAMBRIDGE, Mass. , Dec. 4, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update
Topline clinical secondary efficacy results and primary safety endpoints from Phase 2b ALS trial (PARADIGM) expected in early December 2023 Patients who completed the 18-month PARADIGM trial, includin...
NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readiness
Clinical efficacy top-line results of PARADIGM, a Phase 2b trial in ALS, expected in December 2023 CAMBRIDGE, Mass. , Nov. 13, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences
- Last patient completed the double-blind segment of PARADIGM, a Phase 2b ALS Trial - Clinical efficacy top-line results from PARADIGM expected in December 2023 CAMBRIDGE, Mass. , Nov. 9, 2023 /PRNews...
NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023
Clinical efficacy results ( s econdary endpoints) and safety results (primary endpoints) expected December 2023 Biogen collaboration biomarker results expected Q1 2024 Primary biomarker endpoints to b...
NeuroSense Therapeutics to Participate in BIO-Europe Fall
CAMBRIDGE, Mass. , Nov. 1, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Renowned ALS Researcher Confirms The Efficacy Of NeuroSense Therapeutics' Lead Drug Candidate, PrimeC
HERZLIYA, ISRAEL / ACCESSWIRE / October 19, 2023 / Induced pluripotent stem cells (iPSCs) have emerged as a promising tool in the field of research and therapy for neurodegenerative diseases such as A...
NeuroSense CEO Provides Q3 2023 Update
Phase 2b ALS topline results expected December 2023 CAMBRIDGE, Mass. , Oct. 17, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense's PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC Model
In collaboration with the University of Southern California's Ichida Stem Cell Lab, PrimeC was shown to significantly increase survival rate of induced motor neurons in an in vitro study utilizing ind...
European Medicines Agency Grants NeuroSense SME Status
SME status offers regulatory guidance and engagement in dialogue with EMA NeuroSense to open an EU office in Ulm, Germany Company plans to enroll patients at multiple sites across Europe in its planne...
NeuroSense Granted Patents in Europe, Japan, and Israel for its ALS Drug PrimeC
Patents valid through 2038 Clinical t opline results from Phase 2b ALS trial expected in H2 2023 CAMBRIDGE, Mass. , Sept. 19, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense to Participate in Upcoming ALS Conferences: PACTALS in Malaysia and NEALS in the U.S.
Company to deliver poster presentation regarding its PARADIGM Phase 2b ALS study at NEALS CAMBRIDGE, Mass. , Sept. 14, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.